BPZE1

About ILIAD Biotechnologies

ILIAD Biotechnologies is a private, pre-revenue company advancing a differentiated vaccine platform targeting pertussis (whooping cough). Its core asset, BPZE1, is a live attenuated intranasal vaccine designed to induce mucosal, cellular, and humoral immunity, potentially offering superior and longer-lasting protection compared to current acellular vaccines. With two completed Phase 2 trials, the company is positioned to advance into later-stage development to address a clear unmet medical need in a large global market. ILIAD's strategy focuses on preventing disease in vulnerable populations, particularly infants, and potentially reducing bacterial carriage and transmission.

Therapeutic Areas